Clinical trial NCT01527487: Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
Official title: A Randomized Phase II Study of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: HER2 Negative Breast Cancer
Keywords: breast cancer
eribulin
Halaven
taxotere
Lead sponsor: SCRI Development Innovations, LLC
Sponsor class: OTHER
Collaborators: name: Eisai Inc.
First posted: 2012-02-07
Enrollment: 76
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The investigators propose a randomized phase II study evaluating the pCR and toxicity profiles of combination eribulin/cyclophosphamide (ErC) and docetaxel /cyclophosphamide (TC) as neoadjuvant therapy for locally advanced HER2-negative breast cancer.


Eligibility criteria: Inclusion Criteria:

1. Histologically confirmed invasive adenocarcinoma of the breast.
2. Primary palpable disease confined to the breast and axilla on physical examination (clinical Stage II or III disease). For patients without clinically suspicious axillary adenopathy, the primary must be \>2 cm in diameter by physical examination or imaging studies (clinical T2-3, N0-2, M0). For patients with clinically suspicious axillary adenopathy, the primary breast tumor can be any size (clinical T1-3, N1-2, M0). Patients who have had axillary node dissection and have pN3a (i.e. ≥10 involved axillary nodes) are also eligible.
3. Patients entering the trial after undergoing an axillary node dissection will be eligible if they meet other entry criteria.
4. Estrogen receptor (ER) and progesterone receptor (PR) status in the primary tumor known or pending at the time of study registration.
5. Resolution of all acute effects of surgical procedures to ≤ grade 1. For patients who had or will have, a sentinel node and/or axillary node dissection, completion at least 1 week prior to the initiation of study treatment with a well-healed wound is required.
6. Bilateral, synchronous breast cancer is allowed if both primary tumors are HER2-negative and at least one meets the specified qualifying tumor or nodal inclusion criteria.
7. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0-2.
8. Patients entering this study must be willing to provide release of tumor tissue collected at baseline during a diagnostic procedure if available, and at the time of future surgical procedure(s) for correlative testing. If tissue is not available, the patient will still be eligible for enrollment to the study.
9. No evidence of metastatic disease, as documented by complete staging workup ≤8 weeks prior to initiation of study treatment.
10. No prior treatment for this breast cancer with the exception of criterion #3.
11. HER2-negative tumor status defined as:

    * Immunohistochemical (IHC) 0-1+ or
    * IHC 2+ or IHC 3+ confirmed as FISH (Fluorescence in situ hybridization) or SISH (Silver in situ hybridization) negative (defined by ratio \<2.2)
12. Adequate hematologic function defined as:

    * Absolute neutrophil count (ANC) ≥1500/μL
    * Hemoglobin (Hgb) ≥10 g/dL
    * Platelets ≥100,000/uL
13. Adequate liver function defined as:

    * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5 x the upper limit of normal (ULN)
    * Total bilirubin ≤ the institutional ULN
14. Adequate renal function defined as:

    * Serum creatinine ≤1.5 mg/dL x ULN OR calculated creatinine clearance ≥50 mL/min by the Cockcroft-Gault method:

    GRF =(140-age) x (weight/kg) x (0.85 if female) (72 x serum creatinine mg/dL)
15. Other laboratory testing:

    * Serum magnesium ≥ the institutional lower limit of normal (LLN)
    * Serum potassium ≥the institutional LLN
16. Female and ≥18 years of age.
17. Negative serum pregnancy test within \<7 days prior to initial trial treatment.
18. Female patients who are not of child-bearing potential, and female patients of child-bearing potential who agree to use adequate contraceptive measures that are approved by their study physician while receiving study treatment and continuing for 3 weeks after the last dose of study drug treatment, who are not breastfeeding, and who have a negative serum pregnancy test prior to start of dosing.
19. Willingness and ability to comply with trial and follow-up procedures.
20. Ability to understand the nature of this trial and give written informed consent.

Exclusion Criteria:

1. Clinical T4 lesions, including inflammatory breast cancer. Clinical N3 involvement (e.g., ipsilateral, infraclavicular, supraclavicular, and internal mammary nodes).
2. Peripheral neuropathy (motor or sensory) \> grade 1 according to Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0).
3. Patient has received radiotherapy for treatment of previous cancer that included ≥30% of major bone marrow containing areas (e.g., pelvis, lumbar, spine).
4. Known or suspected allergy or hypersensitivity to any of the study drugs (i.e., eribulin, cyclophosphamide, docetaxel) or known hypersensitivity to polysorbate 80.
5. Patients with acute or chronic liver or renal disease or pancreatitis.
6. Known diagnosis of human immunodeficiency virus (HIV), Hepatitis B (HBV) or Hepatitis C (HCV).
7. Concurrent treatment with an ovarian hormonal replacement therapy or with hormonal agents such as raloxifene, tamoxifen or other selective estrogen receptor modulator (SERM). Patients must have discontinued use of such agents prior to beginning study treatment. However, use of GNRH agonists for the purpose of fertility preservation or suppression of heavy menses is permitted (see Section 5.4.1).
8. Patient has any of the following cardiac diseases currently or within the last 6 months:

   * Left Ventricular Ejection Fraction (LVEF) \<45% as determined by Multiple Gated acquisition (MUGA) scan or echocardiogram (ECHO)
   * Heart rate-corrected QT interval (QTc) \> 480 ms on screening electrocardiogram (ECG) (using Bazett's formula)
   * Unstable angina pectoris
   * Congestive heart failure (New York Heart Association \[NYHA\] ≥ Grade 2
   * Acute myocardial infarction
   * Conduction abnormality not controlled with pacemaker or medication
   * Significant ventricular or supraventricular arrhythmias (Patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible).
   * Valvular disease with significant compromise in cardiac function
9. Chronic use of drugs that cause QTc prolongation. Patients must discontinue use of these drugs 7 days prior to the start of study treatment.
10. Presence of other active cancers, or history of treatment for invasive cancer ≤5 years. Patients with stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e. non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
11. Patients may not receive any other investigational or anti-cancer treatments while participating in this trial.
12. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
13. Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.

Primary outcomes:
measure: Pathologic Complete Response (pCR) Rate in Patients Treated With ErC for 6 Cycles Prior to Surgery
timeFrame: 18 weeks
Secondary outcomes:
measure: The Number of Adverse Events as a Measure of Safety and Tolerability.
timeFrame: 43 months
measure: Clinical Response Rate (cRR) of ErC as Neoadjuvant Therapy
timeFrame: 43 months
measure: Disease-Free Survival (DFS) at 2 Years
timeFrame: 24 months
Other outcomes:
Locations:
city: Ft. Myers
country: United States
facility: Florida Cancer Specialists South
state: Florida
city: Hollywood
country: United States
facility: Memorial Cancer Institute
state: Florida
city: Pensacola
country: United States
facility: Woodlands Medical Specialists
state: Florida
city: St. Petersburg
country: United States
facility: Florida Cancer Specialists North
state: Florida
city: Gainesville
country: United States
facility: Northeast Georgia Medical Center
state: Georgia
city: Portland
country: United States
facility: Mercy Hospital
state: Maine
city: Bethesda
country: United States
facility: Center for Cancer and Blood Disorders
state: Maryland
city: Grand Rapids
country: United States
facility: Grand Rapids Oncology Program
state: Michigan
city: Kansas City
country: United States
facility: Research Medical Center
state: Missouri
city: Omaha
country: United States
facility: Nebraska Methodist Cancer Center
state: Nebraska
city: Cincinnati
country: United States
facility: Oncology Hematology Care, Inc
state: Ohio
city: Columbia
country: United States
facility: South Carolina Oncology Associates
state: South Carolina
city: Nashville
country: United States
facility: Tennessee Oncology
state: Tennessee
city: Fort Worth
country: United States
facility: The Center for Cancer and Blood Disorders
state: Texas
city: Richmond
country: United States
facility: Virginia Cancer Institute
state: Virginia
Study officials:
affiliation: SCRI Development Innovations, LLC
name: Denise A Yardley, MD
role: STUDY_CHAIR
References: